Scholarlink

Background and Objectives <p><i>Helicobacter pylori</i> infection is highly prevalent globally. Standard bismuth quadruple therapy is commonly used in India, but there are growing concerns regarding the emergence of anti-microbial resistance and treatment failure, necessitating the search for newer modalities. This study evaluated the efficacy and safety of adding mastic gum to standard bismuth quadruple therapy (BQTs) for <i>H. pylori</i> eradication.</p> Methods <p>In this single-blind, randomized pilot trial, adults with <i>Helicobacter pylori</i> infection were assigned to receive two&#xa0;weeks' course of either standard bismuth quadruple therapy combined with mastic gum (Group A, <i>n</i> = 32) or bismuth quadruple therapy alone (Group B, <i>n</i> = 32). The primary endpoint was the eradication rate of <i>Helicobacter pylori</i> assessed by urea breath test at six&#xa0;weeks after therapy. Secondary endpoints included symptom improvement, measured by Dyspepsia Symptom Severity Index (DSSI), adverse events and compliance.</p> Results <p>Urea breath test demonstrated higher eradication rates in Group A vs. Group B (85% vs. 67%, absolute risk reduction = 0.18, number needed to treat ≈ six). However, it failed to reach statistical significance (<i>p</i> = 0.19). Both groups showed significant reductions in DSSI scores, with greater mean improvement in Group A (0.941 vs. 0.766, <i>p</i> = 0.001). Both treatment regimens were well-tolerated and treatment compliance was notably high in both groups, with 84.4% in each group reporting 100% compliance.</p> Conclusions <p>In this pilot study, the addition of mastic gum to standard bismuth quadruple therapy resulted in an observed increase in the proportion of eradicated cases; however, it did not meet the primary endpoint due to a lack of statistical significance. Nevertheless, the adjunct therapy was associated with significantly greater dyspepsia symptom relief and was well-tolerated without increasing adverse effects.</p> Graphical Abstract <p>This randomized pilot trial aimed to evaluate the anti-microbial activity of mastic gum, a resinous extract from <i>Pistacia lentiscus</i> when combined with the standard quadruple regimen for <i>H. pylori</i>. The trial found that while the addition of mastic gum resulted in an observed increase in the proportion of eradicated cases, it did not meet the primary endpoint of achieving statistical significance for <i>H. pylori</i> eradication. However, the adjunct therapy significantly improved dyspepsia symptoms without increasing adverse events. <i>DSSI</i>&#xa0;Dyspepsia symptom severity index</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mastic gum as an adjunct therapy to standard bismuth quadruple therapy for Helicobacter pylori eradication: A randomized single-blind pilot study

  • 期刊论文

  • 发表日期：

    2026年3月15日

查看全文
  • Vinay Tulsian,
  • Ravi Kant,
  • Itish Patnaik,
  • Meenakshi Khapre,
  • Kiran Meena,
  • Balachandra Routhu

摘要

Background and Objectives

Helicobacter pylori infection is highly prevalent globally. Standard bismuth quadruple therapy is commonly used in India, but there are growing concerns regarding the emergence of anti-microbial resistance and treatment failure, necessitating the search for newer modalities. This study evaluated the efficacy and safety of adding mastic gum to standard bismuth quadruple therapy (BQTs) for H. pylori eradication.

Methods

In this single-blind, randomized pilot trial, adults with Helicobacter pylori infection were assigned to receive two weeks' course of either standard bismuth quadruple therapy combined with mastic gum (Group A, n = 32) or bismuth quadruple therapy alone (Group B, n = 32). The primary endpoint was the eradication rate of Helicobacter pylori assessed by urea breath test at six weeks after therapy. Secondary endpoints included symptom improvement, measured by Dyspepsia Symptom Severity Index (DSSI), adverse events and compliance.

Results

Urea breath test demonstrated higher eradication rates in Group A vs. Group B (85% vs. 67%, absolute risk reduction = 0.18, number needed to treat ≈ six). However, it failed to reach statistical significance (p = 0.19). Both groups showed significant reductions in DSSI scores, with greater mean improvement in Group A (0.941 vs. 0.766, p = 0.001). Both treatment regimens were well-tolerated and treatment compliance was notably high in both groups, with 84.4% in each group reporting 100% compliance.

Conclusions

In this pilot study, the addition of mastic gum to standard bismuth quadruple therapy resulted in an observed increase in the proportion of eradicated cases; however, it did not meet the primary endpoint due to a lack of statistical significance. Nevertheless, the adjunct therapy was associated with significantly greater dyspepsia symptom relief and was well-tolerated without increasing adverse effects.

Graphical Abstract

This randomized pilot trial aimed to evaluate the anti-microbial activity of mastic gum, a resinous extract from Pistacia lentiscus when combined with the standard quadruple regimen for H. pylori. The trial found that while the addition of mastic gum resulted in an observed increase in the proportion of eradicated cases, it did not meet the primary endpoint of achieving statistical significance for H. pylori eradication. However, the adjunct therapy significantly improved dyspepsia symptoms without increasing adverse events. DSSI Dyspepsia symptom severity index